Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronomic Capecitabine Maintenance in Pancreatic Cancer
NCT03959150Phase 3Unknown
- Sponsor
- Ruijin Hospital
- Start
- Jan 2020
- Primary completion
- Jun 2022
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in pancreatic cancer (PC) comparing Capecitabine Metronomic with Observation (2 arms). Primary endpoint: Disease-Free Survival at 1 year. Status: unknown.
02
Drugs
capecitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT03959150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03959150.